Navigation Links
Carrington Reports Third Quarter 2007 Results

- Revenues Down from Same Quarter Last Year

- Second Consecutive Double Digit Quarter-to-Quarter Revenue Gain

- DelSite Continues Toward Phase I Vaccine Clinical Trial

IRVING, Texas, Nov. 27 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (OTC Bulletin Board: CARN) today reported revenue for the quarter ended September 30, 2007 of $6.5 million, compared to $6.7 million in the year-ago period, as the Company discontinued certain unprofitable or marginally profitable products during the third quarter of the current year. However, the revenue in the quarter just ended, was 16 percent higher than the $5.6 million revenue reported for the second quarter of 2007, the second consecutive quarter-to-quarter revenue gain this year.

Medical Services revenue for the third quarter of 2007, at $1.9 million, was down from the year-ago level of $2.3 million. Consumer Services revenue grew 5 percent for the quarter, to $3.8 million from $3.6 million in the year-ago period. Grant income received for funding of research for the Company's wholly-owned drug delivery subsidiary, DelSite Biotechnologies, Inc., decreased by 4 percent for the quarter, to $776,000 from $811,000 a year ago.

Net loss for the third quarter of 2007, including $524,000 of net funding of DelSite, was $2.2 million, or 21 cents per basic and diluted share, an increase of $485,000 from the net loss reported for the year-ago quarter of $1.7 million, or 16 cents per basic and diluted share. Pro forma loss for the quarter, exclusive of DelSite net funding, was $1.7 million compared to a $1.1 million pro forma loss in the prior-year period.

"We continue on the road to bringing growth and profitability to our core business," said Carlton E. Turner, PhD, Carrington's CEO. "Our product revenue and margins improved again this quarter as we grew our more profitable product lines and reduced our overall operating costs."

Commenting on DelSite, Dr. Turner stated, "We continue to focus our strategy on building the clinical foundation of the GelSite(R) polymer drug delivery and adjuvant technologies and on moving them toward commercial introduction. We are seeing increasing interest from both commercial companies and government health agencies in our vaccine and therapeutic delivery systems for both nasal and injectible formulations. In addition, we continue on the path toward filing an IND and conducting a Phase I clinical study in early 2008 of the GelVac(TM) nasal powder influenza H5N1 (bird flu) vaccine."

Conference Call Scheduled

Investors are invited to listen to the conference call scheduled on Tuesday, November 27, 2007, at 4.30 p.m. Eastern, 3.30 p.m. Central, by dialing 1-866-825-3209 in the US or 617-213-8061 internationally. The pass code is 13738306. The call is also being web cast by CCBN and can be accessed at Carrington's website at A replay of the call will be available a few hours after the call concludes by dialing 1-888-286-8010 in the US and 617-801-6888 internationally. The pass code for the replay is 83847473.

The web cast is also being distributed through the Thomson StreetEvents Network to both institutional and individual investors. Individual investors may listen to the call at, Thomson/CCBN's individual investor portal, powered by StreetEvents. Institutional investors may access the call via Thomson's password-protected event management site, StreetEvents (

About Carrington

Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington's DelSite Biotechnologies subsidiary is developing its proprietary GelSite(R) technology which is designed to provide controlled release of peptide and protein-based drugs. Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit

Non-GAAP Financial Information

This press release contains the non-generally accepted accounting principle financial measure of Pro forma loss, which is defined as net loss excluding net DelSite expenses. The amounts included in the calculation of this measure are computed in accordance with generally accepted accounting principles (GAAP). We believe this measure is useful to investors because it may provide users of this financial information with a meaningful measure of the Company's profitability before funding the research and development activities of its DelSite subsidiary. Pro forma loss is not a measure of financial performance under GAAP and thus should not be considered in isolation. Furthermore, it should not be seen as a substitute for metrics prepared in accordance with GAAP. Our reconciliation of this measure to net loss is included in the following tables.

Certain statements in this release concerning Carrington may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and, a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission.


Condensed Consolidated Statements of Operations


(in thousands, except per share amounts)

Three Months Ended Nine Months Ended

September 30, September 30,

2007 2006 2007 2006


Medical Services $1,842 $2,161 $5,991 $6,383

Royalty income 104 104 312 312

Medical Services, total 1,946 2,265 6,303 6,695

Consumer Services 3,767 3,580 9,128 12,465

Grant income, DelSite 776 811 1,399 1,506

Total revenues 6,489 6,656 16,830 20,666

Cost and expenses:

Cost of product sales 4,428 4,615 12,418 15,257

Selling, general and

administrative 1,935 1,884 5,724 5,652

Research and development 151 171 459 536

Research and development -

DelSite 1,300 1,503 3,575 3,985

Other income (8) (19) (25) (36)

Interest expense, net 932 266 1,771 723

Net income (loss) before

income taxes (2,249) (1,764) (7,092) (5,451)

Provision for income taxes - - - -

Net income (loss) $(2,249) $(1,764) $(7,092) $(5,451)

Net income (loss) per

common share -

basic and diluted $(0.21) $ (0.16) $(0.65) $(0.50)

Weighted average shares

outstanding -

Basic and diluted 10,927 10,884 10,912 10,843

Reconciliation of Non-GAAP

Financial Measures:

Net income (loss) $(2,249) $(1,764) $(7,092) $(5,451)

Less: DelSite grant income 776 811 1,399 1,506

Plus: DelSite expenses 1,300 1,503 3,575 3,985

Pro forma profit (loss)

before DelSite $(1,725) $(1,072) $(4,916) $(2,972)


Condensed Consolidated Balance Sheets

(in thousands)

September 30, December 31,

2007 2006

(unaudited) (audited)


Current Assets:

Cash and cash equivalents $3,253 $878

Cash, restricted 489 -

Accounts receivable, net 2,337 2,659

Inventories, net 3,786 3,405

Prepaid expenses 427 155

Total current assets 10,292 7,097

Property, plant and equipment, net 5,460 6,093

Customer relationships, net 55 199

Other assets, net 1,547 609

Total assets $17,354 $13,998


Current Liabilities:

Line of credit $2,000 $ 1,811

Accounts payable 2,572 1,324

Accrued liabilities 1,972 1,820

Current portion of long-term debt and capital

lease obligations 1,088 203

Deferred revenue 610 903

Total current liabilities $8,242 $ 6,061

Long-term debt and capital lease obligations,

net of debt discount 8,272 3,745

Commitments and contingencies - -

Shareholders' Equity:

Common stock 110 109

Capital in excess of par value 61,214 57,475

Accumulated deficit (60,481) (53,389)

Treasury stock at cost (3) (3)

Total shareholders' equity 840 4,192

Total liabilities and shareholders' equity $ 17,354 $13,998

SOURCE Carrington Laboratories, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
2. Carrington Reports Second Quarter 2007 Results
3. Carrington Completes $8 Million Financing
4. Carrington Reports on ISO 9001:2000 Inspection at Sabila Industrial in Costa Rica
5. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
6. Carrington and DaySpring Pharma Extend and Formalize Agreement for Distribution of Diabetic and Radiation Products Into Physician Market
7. Carrington Laboratories Common Stock Now Trading on the OTC Bulletin Board: CARN.OB
8. Carrington Reports on ISO 9001:2000 Inspection
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. QMed, Inc. Reports July Medicare SNP Enrollments
11. Phlo Affiliate Reports Expanded Coverage to Oregon Border
Post Your Comments:
(Date:3/27/2017)... ... March 27, 2017 , ... A research team led ... grafts in JoVE’s Video Journal, the world’s first peer-reviewed scientific video journal. The ... treating coronary artery disease (CAD). Lam is an assistant professor at the Department ...
(Date:3/24/2017)... Md. , March 24, 2017  Infectex Ltd., ... (MBVF), today announced positive results of a Phase 2b-3 ... therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). ... scientists at Sequella, Inc. ( USA ) ... A total of 140 patients were enrolled in ...
(Date:3/24/2017)... LEXINGTON, Mass. , March 24, 2017 ... pipeline of immune checkpoint antibodies and cancer vaccines, today ... The 7 th  Annual William Blair and Maidstone ... Event Space Alexandria Center in New York, ... March 29 at 9:40 am: ...
(Date:3/23/2017)... 23, 2017  SeraCare Life Sciences, Inc., a ... vitro diagnostics manufacturers and clinical laboratories, is ... multiplexed Inherited Cancer reference material ... next-generation sequencing (NGS). The Seraseq™ Inherited Cancer DNA ... from industry experts to validate the ability ...
Breaking Biology Technology:
(Date:3/7/2017)... Brandwatch , the leading social intelligence company, today announces that it ... insights to support its reporting, help direct future campaigns, and share ... charity will be using Brandwatch Analytics social listening and analytics technology ... the topics and issues that are a priority for its supporters. ... "Until recently we,ve ...
(Date:3/2/2017)... 2, 2017 Summary This report provides ... its partnering interests and activities since 2010. ... Read the full report: ... since 2010 report provides an in-depth insight into the partnering ... On demand company reports are prepared upon purchase ...
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
Breaking Biology News(10 mins):